Antibody Engineering & Therapeutics Asia is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Jochen G. Salfeld is leading the AbbVie Global Biologics Department as a Distinguished Research Fellow of the AbbVie Community of Science (ACOS) and as Vice President Global Biologics Discovery at the AbbVie Bioresearch Center (ABC) in Worcester, MA, USA.
Jochen studied in Germany, took his doctorate from Heidelberg University and completed his post-doc at the Center of Molecular Biology in Heidelberg, Germany, the Yang-Ming Medical College in Taipei, Taiwan and the Dana Farber Cancer Institute of Harvard Medical School in Boston, Massachusetts.
Jochen joined the BASF Bioresearch Corporation start-up in Cambridge, Massachusetts in 1990 – in 2001 acquired by Abbott along with BASF Pharma – and led the discovery team that collaborated with Cambridge Antibody Technology, Cambridge, UK, in the discovery of the first fully human Anti-TNF antibody D2E7, today Adalimumab (HUMIRAâ). Upon transition into development Jochen was named the first International Project Manager for D2E7 with different roles as the clinical development progressed.
In parallel he systematically expanded the team starting from a small group of scientists into a large department supporting today all Therapeutic Areas of AbbVie, including Immunology, Cancer Research, Neuroscience, Virology and beyond.
Global Biologics works on identifying the optimal therapeutics for selected therapeutic mechanisms including antibodies, multi-specifics, antibody-drug conjugates, immune-cytokines, soluble T-cell receptors and is engaged in many technology development projects.